Every GLP-1, compared.
Weight-loss efficacy, mechanisms, approval status and dosing across all GLP-1 and incretin-based therapies.
- Mechanism
- Triple
- Dosing
- Weekly
- Max dose
- 12mg
Triple agonist, largest published weight loss
Calculator →- Mechanism
- GLP-1/GIP
- Dosing
- Weekly
- Max dose
- 15mg
Dual mechanism, superior weight loss
Calculator →- Mechanism
- Amylin/GLP-1
- Dosing
- Weekly
- Max dose
- 2.4mg/2.4mg
Dual amylin + GLP-1 pathways
Calculator →- Mechanism
- GLP-1/Glucagon
- Dosing
- Weekly
- Max dose
- 2.4mg
MASH focus, liver health
Calculator →- Mechanism
- GLP-1/Glucagon
- Dosing
- Weekly
- Max dose
- 4.8mg
Glucagon arm, MASH interest
Calculator →- Mechanism
- GLP-1
- Dosing
- Weekly
- Max dose
- 2.4mg
Gold standard, extensive safety data
Calculator →- Mechanism
- GLP-1/Glucagon
- Dosing
- Weekly
- Max dose
- 6mg
Glucagon boost, liver benefits
Calculator →- Mechanism
- GLP-1
- Dosing
- Daily
- Max dose
- 36mg
Oral, once daily
Calculator →- Mechanism
- Amylin
- Dosing
- Weekly
- Max dose
- 2.4mg
Novel amylin pathway, complements GLP-1
Calculator →Weight loss percentages from clinical trials. Individual results vary. Discuss options with a healthcare provider.
Read the detail.
Understanding the mechanisms.
Glucagon-like peptide-1 reduces appetite and slows gastric emptying. The foundation of this drug class.
Adding GIP (glucose-dependent insulinotropic polypeptide) enhances insulin secretion and may reduce nausea.
Glucagon component increases energy expenditure and may improve liver fat metabolism.
Combines GLP-1, GIP, and Glucagon for maximum metabolic impact across multiple pathways.
Amylin analogs work on different satiety pathways, complementing GLP-1 effects.
CagriSema combines amylin (Cagrilintide) with GLP-1 (Semaglutide) for dual-pathway action.
Want to dig deeper?
The comparison tool puts compounds side by side — mechanism, dosing, half-life and stability — and filters by preset stacks.
Open comparison tool